Skip to main content

Table 1 Demographics and clinical characteristics split by pathological diagnosis group

From: Assessment of genetic risk for improved clinical-neuropathological correlations

  Pathological diagnosis group
Control FTD DLB AD + DLB AD AD + MTLS
Participants, N 177 64 56 442 1799 175
Women, N (%) 94 (53) 25 (39) 12 (21)*§¶# 181 (41)*¶# 959 (53) 94 (54)
Age at death, y 83.7 (8.7) 78.5 (11.5)*# 80.1 (8.6)*# 79.0 (8.5)*#¶ 80.2 (9.0)*# 84.6 (7.8)
Caucasian, N (%) 173 (98) 63 (98) 56 (100) 427 (97) 1736 (96) 171 (98)
Hispanic, N (%) 4 (2) 0 (0) 1 (2) 7 (2) 30 (2) 1 (1)
Education, y 15.4 (2.8) 15.1 (3.0) 15.6 (3.3) 15.0 (3.2) 14.3 (3.3)*ठ14.8 (3.6)
Final clinical evaluation
Time before death, y 2.6 (3.0) 3.0 (3.0) 2.9 (3.5) 3.0 (3.3) 2.5 (2.8)§# 3.2 (3.1)
Primary clinical diagnosis
 AD, N (%) 0 (0) 22 (34) 19 (34) 340 (77) 1574 (87) 159 (91)
 LBD, N (%) 0 (0) 2 (3) 24 (43) 79 (18) 41 (2) 4 (2)
 FTD, N (%) 0 (0) 23 (36) 1 (2) 9 (2) 64 (4) 5 (3)
Global CDR 0.1 (0.2) 1.6 (1.2)* 1.4 (1.0)* 2.1 (0.9)*†‡ 1.9 (1.0)*†‡§# 2.2 (0.8)*†‡
CDR-SB 0.1 (0.4) 9.0 (6.8)* 7.6 (5.8)* 12.5 (5.5)*†‡ 10.8 (6.1)*†‡§# 12.9 (4.9)*†‡
  1. Reported as mean (SD) unless otherwise noted. Primary clinical diagnosis of AD included probable or possible AD, LBD included DLB, Lewy body variant of AD, and LBD, and FTD included FTD, Pick’s disease, CBD, PSP, and PPA. FDR adjusted p < .05 for differences from *Control, †FTD, ‡DLB, §AD + DLB, ¶AD, or #AD + MTLS based on pairwise Pearson’s Chi squared tests or Welch’s t-tests. Small numbers in certain subgroups prevented the pairwise comparison of primary clinical diagnoses across pathologically defined groups
  2. Abbreviations: DLB, dementia with Lewy bodies; AD, Alzheimer’s disease; FTD, frontotemporal lobar degeneration; MTLS, medial temporal lobe sclerosis; LBD, Lewy body dementia; CDR, Clinical Dementia Rating Scale; CDR-SB, Clinical Dementia Rating Scale Sum of Boxes